**Washington State Pharmacy and Therapeutics Committee**  
**Drug Utilization Review Board**  
**Date:** February 19, 2020  
**Time:** 9 a.m. to 12 p.m.  
**Port of Seattle “International A” Conference Room**  
Seattle-Tacoma International Airport  
17801 International Blvd., Seattle, WA 98158

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 a.m.</td>
<td>Welcome &amp; Introductions</td>
<td>Ginni Buccola, Committee Chair</td>
</tr>
</tbody>
</table>
| 9:05 a.m. | Newer Diabetes- draft report  
Incretin Mimetics/Enhancers  
- Amylin Analogs  
- DPP4 inhibitors  
- GLP1 Agonists  
- SGLT2 Inhibitors  
- DPP4 Inhibitor/SGLT2 Inhibitor Combinations  
- DPP4 Inhibitor/TZD Combinations  
- GLP1 Agonist/Insulin Combinations  
  - Stakeholder input*  
  - P&T Motion | Rosalie Kelly, DERP  
Umang Patel, Magellan |
| 10:25 a.m. | Pharmacy & Therapeutics Committee Adjourns  
Drug Utilization Review (DUR) Board Convenes | Ginni Buccola, Committee Chair |
| 10:25 a.m. | Insulin and related agents  
- Rapid Acting  
- Short Acting  
- Pre-Mixed  
- Intermediate Acting  
- Long Acting  
  - Stakeholder input*  
  - Motion  
  - Incretin Mimetics/Enhancers | Umang Patel, Magellan |
| 10:40 a.m. | SGLT2 Inhibitors  
- Stakeholder input*  
- Motion | Umang Patel, Magellan |
| 10:45 a.m. | Thiazolidinediones  
- Stakeholder input*  
- Motion | Umang Patel, Magellan |
| 10:50 a.m. | Pancreatic Enzymes  
- Stakeholder input*  
- Motion | Umang Patel, Magellan |
| 10:55 a.m. | Growth Hormone & Growth Factors  
- Growth Hormone Releasing Hormones (GHRH)  
- Growth Hormones  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |

* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
  Committee discussion and motions will follow stakeholder comments.  
  The times noted are estimates and subject to change.  
  If you are a person with a disability and need a reasonable accommodation or have questions  
  please call Leta Evaskus at 206-521-2029.
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 11:20 a.m. | Ulcerative Colitis Agents  
- Inflammatory Bowel Agents  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 11:30 a.m. | Cystic Fibrosis Agents  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 11:40 a.m. | Inhaled Antibiotics  
  - Aminoglycosides  
  - Monobactams  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 11:45 a.m. | Anticoagulants: Factor Xa and Thrombin Inhibitors  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 11:50 a.m. | Topical Antiparasitics: Scabicides and Pediculicides  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 11:55 a.m. | Lipotropics  
  - PCSK-9 Inhibitors  
  - Microsomal Triglyceride Transfer Protein Inhibitor (MTP)  
  - Stakeholder input*  
  - Motion | Umang Patel, Magellan |
| 12 p.m.   | **Drug Utilization Review Board Adjourns** | Ginni Buccola, Committee Chair |

* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.